Skip to content
Catalyst

γ-tocopherolWhat was measured

Measured, with no finding

171 endpoints

Show what was measuredHide what was measured
  • baseline FMD

    no effect, p = 0.05

    Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)

    PMID 22841396 · one of two readings recorded this

  • baseline plasma ADMA

    no effect, p = 0.05

    Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)

    PMID 22841396 · one of two readings recorded this

  • baseline plasma arginine

    no effect, p = 0.05

    Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)

    PMID 22841396 · one of two readings recorded this

  • baseline plasma MDA

    no effect, p = 0.05

    Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05)

    PMID 22841396 · one of two readings recorded this

  • fasting baseline FMD, MDA, arginine and ADMA

    no effect, unaffected (P>.05), no per-endpoint estimate

    Not recorded as a finding: One sentence covers four endpoints with a single P value and no per-endpoint estimate, and it is the fasting baseline, which would sit beside the postprandial MDA claim on the same node and could be misread as its opposite. Nodes exist for FMD, MDA, ADMA and plasma arginine.

    Baseline FMD, MDA, arginine and ADMA were unaffected by γ-TmT (P>.05).

    PMID 22841396 · one of two readings recorded this

  • inflammatory proteins

    no effect

    Inflammatory proteins were unaffected by glucose ingestion or γ-TmT

    PMID 22841396 · one of two readings recorded this

  • plasma ADMA/arginine ratio after glucose ingestion

    decreases, p = 0.05

    the ratio of ADMA/arginine increased time-dependently in both trials (P<.05), but to a lesser extent following γ-TmT supplementation (P<.05)

    PMID 22841396 · one of two readings recorded this

  • plasma ADMA/arginine ratio after glucose ingestion

    increases, p = 0.05

    the ratio of ADMA/arginine increased time-dependently in both trials (P<.05), but to a lesser extent following γ-TmT supplementation (P<.05)

    PMID 22841396 · one of two readings recorded this

  • plasma ADMA/arginine ratio during the 3-h postprandial period

    decreases, ratio increased time-dependently in both trials, but to a lesser extent after γ-TmT

    Not recorded as a finding: The measured construct is a ratio of ADMA to arginine. The nearest nodes (CAT:outcome/adma, CAT:outcome/arginine-ornithine-ratio) measure ADMA alone or arginine-to-ornithine, so this is a no_outcome_node case.

    However, the ratio of ADMA/arginine increased time-dependently in both trials (P<.05), but to a lesser extent following γ-TmT supplementation (P<.05).

    PMID 22841396 · one of two readings recorded this

  • plasma ADMA

    no effect

    Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA

    PMID 22841396 · one of two readings recorded this

  • plasma arginine after glucose ingestion

    decreases, p = 0.05

    Plasma arginine decreased (P<.05) in both trials to a similar extent regardless of γ-TmT supplementation

    PMID 22841396 · one of two readings recorded this

  • plasma arginine

    no effect

    Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA

    PMID 22841396 · one of two readings recorded this

  • plasma γ-carboxyethyl-hydroxychroman

    increases, p = 0.05

    Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA

    PMID 22841396 · one of two readings recorded this

  • plasma glucose

    no effect

    Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA

    PMID 22841396 · one of two readings recorded this

  • plasma inflammatory proteins (unspecified panel) during the postprandial period

    no effect, unaffected by glucose ingestion or γ-TmT

    Not recorded as a finding: Agentless-style sentence, and the abstract names no individual protein, so no listed node (for example CAT:outcome/tnf-alpha or interleukin-6) can be chosen.

    Inflammatory proteins were unaffected by glucose ingestion or γ-TmT.

    PMID 22841396 · one of two readings recorded this

  • plasma γ-tocopherol

    increases, p = 0.05

    Supplementation of γ-TmT increased (P<.05) plasma γ-T by threefold and γ-carboxyethyl-hydroxychroman by more than ninefold without affecting α-T, glucose, arginine or ADMA

    PMID 22841396 · one of two readings recorded this

  • postprandial brachial artery flow-mediated dilation (FMD) after a 75 g oral glucose load, 3-h period

    FMD decreased 30%-44% after glucose ingestion; maintained with γ-TmT

    Not recorded as a finding: The only sentence says FMD 'was maintained with γ-TmT' after falling 30%-44% following glucose ingestion. 'Maintained' reports preservation against a fall, not an increase, and the sentence states no between-trial contrast, so no direction token fits without adding one the sentence does not contain. Node CAT:outcome/flow-mediated-dilation exists.

    Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT.

    PMID 22841396 · one of two readings recorded this

  • postprandial brachial artery flow-mediated dilation over 3 h after a 75 g oral glucose load

    FMD decreased 30%-44% after glucose ingestion (P<.05) in the comparison trial

    Not recorded as a finding: flow-mediated-dilation node fits, but 'was maintained with γ-TmT' describes preservation within the supplemented trial and states no between-trial contrast or direction versus the unsupplemented trial; recording increases would be inferred

    Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT.

    PMID 22841396 · one of two readings recorded this

  • postprandial FMD after glucose ingestion

    no effect

    Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT

    PMID 22841396 · one of two readings recorded this

  • postprandial FMD after glucose ingestion

    decreases, p = 0.05

    Postprandial FMD decreased 30%-44% (P<.05) following glucose ingestion, but was maintained with γ-TmT

    PMID 22841396 · one of two readings recorded this

  • postprandial increase in MDA after glucose ingestion

    decreases

    Supplementation of γ-TmT also attenuated postprandial increases in MDA that occurred following glucose ingestion

    PMID 22841396 · one of two readings recorded this

  • postprandial plasma malondialdehyde after glucose ingestion, assay not stated

    decreases

    Not recorded as a finding: malondialdehyde-circulating node requires the assay (TBARS or HPLC) recorded with each finding and the abstract never states it

    Supplementation of γ-TmT also attenuated postprandial increases in MDA that occurred following glucose ingestion.

    PMID 22841396 · one of two readings recorded this

  • brachial artery flow-mediated dilation (FMD)

    increases, p = 0.05

    Smoking cessation with γ-T-rich supplementation increased FMD responses by 1.3% (P<0.05) beyond smoking cessation alone (4.1 ± 0.6% vs 2.8 ± 0.3%; mean ± SEM)

    PMID 24075893 · one of two readings recorded this

  • plasma cotinine

    decreases

    Smoking cessation regardless of supplementation similarly decreased plasma cotinine

    PMID 24075893 · one of two readings recorded this

  • plasma malondialdehyde, assay not stated

    decreased similarly in both groups (P<0.05)

    Not recorded as a finding: The finding sits in a clause that does not name the compound and reports a similar fall in both groups, which is a within-arm change in each arm rather than a stated between-arm contrast. Node CAT:outcome/malondialdehyde-circulating exists.

    Although plasma malondialdehyde decreased similarly in both groups (P<0.05), plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation.

    PMID 24075893 · both readings recorded this

  • plasma malondialdehyde

    decreases, p = 0.05

    Although plasma malondialdehyde decreased similarly in both groups (P<0.05)

    PMID 24075893 · one of two readings recorded this

  • plasma myeloperoxidase vs FMD

    decreases, p = 0.05

    these were inversely related to FMD (P<0.05; R=-0.46 and -0.37, respectively)

    PMID 24075893 · one of two readings recorded this

  • plasma myeloperoxidase

    decreases, p = 0.05

    Plasma TNF-α and myeloperoxidase decreased (P<0.05) only in those receiving γ-T-rich supplements

    PMID 24075893 · one of two readings recorded this

  • plasma oxidized LDL and urinary F2-isoprostanes, assay not stated

    no effect, unaffected by smoking cessation or γ-T-rich supplementation

    Not recorded as a finding: No listed outcome node for oxidized LDL or urinary F2-isoprostanes.

    Although plasma malondialdehyde decreased similarly in both groups (P<0.05), plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation.

    PMID 24075893 · one of two readings recorded this

  • plasma oxidized LDL

    no effect

    plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation

    PMID 24075893 · one of two readings recorded this

  • plasma TNF-α, immunoassay not stated

    decreases

    Not recorded as a finding: the only sentence reports a within-arm decrease 'only in those receiving' the supplement, not a between-arm contrast (within_arm_only); the tnf-alpha node would otherwise fit

    Plasma TNF-α and myeloperoxidase decreased (P<0.05) only in those receiving γ-T-rich supplements and these were inversely related to FMD (P<0.05; R=-0.46 and -0.37, respectively).

    PMID 24075893 · both readings recorded this

  • plasma TNF-α vs FMD

    decreases, p = 0.05

    these were inversely related to FMD (P<0.05; R=-0.46 and -0.37, respectively)

    PMID 24075893 · one of two readings recorded this

  • plasma TNF-α

    decreases, p = 0.05

    Plasma TNF-α and myeloperoxidase decreased (P<0.05) only in those receiving γ-T-rich supplements

    PMID 24075893 · one of two readings recorded this

  • plasma γ-tocopherol

    increases, p = 0.05

    γ-T-rich supplementation increased plasma γ-T by seven times and its urinary metabolite γ-carboxyethyl hydroxychroman by nine times (P<0.05)

    PMID 24075893 · one of two readings recorded this

  • urinary γ-carboxyethyl hydroxychroman

    increases, p = 0.05

    γ-T-rich supplementation increased plasma γ-T by seven times and its urinary metabolite γ-carboxyethyl hydroxychroman by nine times (P<0.05)

    PMID 24075893 · one of two readings recorded this

  • urinary F2-isoprostanes

    no effect

    plasma oxidized LDL and urinary F2-isoprostanes were unaffected by smoking cessation or γ-T-rich supplementation

    PMID 24075893 · one of two readings recorded this

  • FEV1 and FEV1/FVC

    no effect

    no clinically or statistically significant changes were seen in FEV1 or FEV1/FVC from measurements taken during the initial baseline visit

    PMID 28736267 · one of two readings recorded this

  • induced sputum neutrophil percentage (%PMNs, cytocentrifuge differential with modified Wright stain), change from post-treatment to 6 h and 24 h after inhaled LPS challenge (primary endpoint); induced sputum eosinophils (%, and per mg sputum) after 14 days of treatment, pre-challenge (primary endpoint); sputum total mucins and MUC5AC by refractometry and mass spectrometry; mucociliary clearance by 99mTc sulfur colloid gamma scintigraphy; sputum cytokines IL-1β, IL-6 and IL-8 by multiplex immunoassay

    decreases, γT attenuated the LPS-induced rise in sputum %PMNs versus placebo at 6 h (p=0.04) and at 24 h (p=0.02), p = 0.04

    Not recorded as a finding: this platform holds no node for the endpoint

    Linear mixed modeling demonstrated that γT treatment (compared to placebo) significantly attenuated sputum %PMNs at both 6 (p=0.04) and 24 hours (p=0.02) after LPS challenge.

    PMID 28736267 · one of two readings recorded this

  • LPS-induced change in sputum PMNs per mg

    no effect, p = 0.2

    PMNs/mg Δ 236.2 ± 692.7 SD, p=0.2

    PMID 28736267 · one of two readings recorded this

  • LPS-induced change in sputum PMNs per mg

    increases, p = 0.01

    PMNs/mg Δ 384.1 ± 531.2 SD, p<0.01

    PMID 28736267 · one of two readings recorded this

  • LPS-induced change in sputum %PMNs

    increases, p = 0.04

    % PMNS Δ 11.7% ± 20.7 SD, p=0.04

    PMID 28736267 · one of two readings recorded this

  • LPS-induced change in sputum %PMNs

    increases, p = 0.01

    %PMNs: Δ 20.1% ± 16.5 SD, p<0.01

    PMID 28736267 · one of two readings recorded this

  • LPS-induced sputum inflammatory cytokines

    no effect

    we did not detect a significant γT treatment effect on LPS-induced inflammatory cytokine concentrations in sputum following LPS challenge

    PMID 28736267 · one of two readings recorded this

  • LPS-induced sputum %PMNs, γT vs placebo

    decreases, p = 0.02

    Linear mixed modeling demonstrated that γT treatment (compared to placebo) significantly attenuated sputum %PMNs at both 6 (p=0.04) and 24 hours (p=0.02) after LPS challenge

    PMID 28736267 · one of two readings recorded this

  • LPS-induced sputum %PMNs, γT vs placebo

    decreases, p = 0.04

    Linear mixed modeling demonstrated that γT treatment (compared to placebo) significantly attenuated sputum %PMNs at both 6 (p=0.04) and 24 hours (p=0.02) after LPS challenge

    PMID 28736267 · one of two readings recorded this

  • mucociliary clearance (MCC) after LPS challenge

    no effect, p = 0.6

    there was no such slowing of MCC by LPS challenge during active treatment (MCC = 20.2 ± 8.0% post-challenge vs. 21.4 ± 9.7% post-treatment, p=0.6)

    PMID 28736267 · one of two readings recorded this

  • mucociliary clearance (MCC) after LPS challenge

    decreases, p = 0.01

    MCC was significantly slowed following LPS challenge compared to post-treatment measurements for the placebo treatment period (MCC = 16.3 ± 9.3% post-challenge vs. 21.4 ± 6.9% post-treatment, p < 0.01)

    PMID 28736267 · one of two readings recorded this

  • post-treatment induced-sputum percentage eosinophils and eosinophils per mg sputum (primary endpoint, cytocentrifuge differential), after 14 days of a gamma-tocopherol-enriched supplement (2 geltabs once daily, each 612 mg gamma-tocopherol, 7 mg alpha-tocopherol, 28 mg beta-tocopherol, 8 mg delta-tocopherol; Callion Pharma; tocopherols only) versus safflower oil placebo in mild asthma; also measured: LPS-induced sputum neutrophilia, sputum mucins and MUC5AC, mucociliary clearance by gamma scintigraphy, sputum cytokines

    decreases, post-treatment sputum %eosinophils p=0.04; eosinophils/mg of sputum p=0.01, p = 0.04

    Not recorded as a finding: this platform holds no node for the endpoint

    Using the linear mixed model approach, we found that γT treatment significantly reduced post-treatment sputum %eosinophils (p=0.04) and eosinophils/mg of sputum (p=0.01) compared to placebo.

    PMID 28736267 · one of two readings recorded this

  • post-treatment sputum eosinophils per mg

    decreases, p = 0.01

    γT treatment significantly reduced post-treatment sputum %eosinophils (p=0.04) and eosinophils/mg of sputum (p=0.01)

    PMID 28736267 · one of two readings recorded this

  • post-treatment sputum %eosinophils

    decreases, p = 0.04

    γT treatment significantly reduced post-treatment sputum %eosinophils (p=0.04) and eosinophils/mg of sputum (p=0.01)

    PMID 28736267 · one of two readings recorded this

  • post-treatment sputum MUC5AC content

    decreases, p = 0.0001

    γT treatment significantly reduced post-treatment total mucins (p=0.03) and MUC5AC content (p<0.0001) compared to placebo

    PMID 28736267 · one of two readings recorded this

  • post-treatment total sputum mucins

    decreases, p = 0.03

    γT treatment significantly reduced post-treatment total mucins (p=0.03) and MUC5AC content (p<0.0001) compared to placebo

    PMID 28736267 · one of two readings recorded this

  • PT, aPTT and INR

    no effect

    No significant change in PT, aPTT, or INR was observed

    PMID 28736267 · one of two readings recorded this

  • regional deposition indices (C/P, skew) and 24-hour retention

    no effect

    There were no differences in regional deposition indices (C/P or skew) nor in 24-hour retention between post-treatment and post-challenge measurements for either treatment period

    PMID 28736267 · one of two readings recorded this

  • serum γ-CEHC

    increases, p = 0.0001

    Serum γT and γ-CEHC concentrations rose significantly from baseline values in the active treatment group only (p<0.0001 for both)

    PMID 28736267 · one of two readings recorded this

  • serum γ-tocopherol

    increases, p = 0.0001

    Serum γT and γ-CEHC concentrations rose significantly from baseline values in the active treatment group only (p<0.0001 for both)

    PMID 28736267 · one of two readings recorded this

  • sputum eosinophilia following LPS challenge

    no effect

    There was no effect of inhaled LPS challenge or γT treatment on any measure of sputum eosinophilia following LPS challenge

    PMID 28736267 · one of two readings recorded this

  • sputum IL-1β after LPS challenge

    no effect, p = 0.07

    no significant LPS-induced increase was observed during the active treatment period (p=0.07 and p=0.40, respectively)

    PMID 28736267 · one of two readings recorded this

  • sputum IL-1β after LPS challenge

    increases, p = 0.002

    During the placebo period, sputum IL-1β and IL-8 concentrations were significantly increased 6 hours post-LPS challenge compared to post-treatment values (p=0.002 and p=0.01, respectively)

    PMID 28736267 · one of two readings recorded this

  • sputum IL-6 after LPS challenge

    no effect

    There was no significant LPS-induced change in sputum IL-6 concentration during either treatment period

    PMID 28736267 · one of two readings recorded this

  • sputum IL-8 after LPS challenge

    no effect, p = 0.4

    no significant LPS-induced increase was observed during the active treatment period (p=0.07 and p=0.40, respectively)

    PMID 28736267 · one of two readings recorded this

  • sputum IL-8 after LPS challenge

    increases, p = 0.01

    During the placebo period, sputum IL-1β and IL-8 concentrations were significantly increased 6 hours post-LPS challenge compared to post-treatment values (p=0.002 and p=0.01, respectively)

    PMID 28736267 · one of two readings recorded this

  • sputum MUC5AC concentration after LPS challenge

    no effect

    We found no significant difference in MUC5AC concentrations between the treatment groups at the same time point (data not shown)

    PMID 28736267 · one of two readings recorded this

  • sputum MUC5AC content after LPS challenge

    increases, p = 0.0004

    MUC5AC content was significantly increased from post-treatment levels in both treatment groups 6 hours after inhaled LPS challenge [p=0.001 (placebo), p=0.0004 (active)]

    PMID 28736267 · one of two readings recorded this

  • sputum MUC5AC content after LPS challenge

    increases, p = 0.001

    MUC5AC content was significantly increased from post-treatment levels in both treatment groups 6 hours after inhaled LPS challenge [p=0.001 (placebo), p=0.0004 (active)]

    PMID 28736267 · one of two readings recorded this

  • sputum %PMNs after LPS challenge

    increases, p = 0.003

    Inhaled LPS challenge significantly increased sputum percent neutrophils (%PMNs) (p=0.003) and neutrophils per mg (PMNs/mg) of sputum (p=0.01) at 6 hours compared to post-treatment sputum during the placebo period

    PMID 28736267 · one of two readings recorded this

  • sputum PMNs per mg after LPS challenge

    increases, p = 0.01

    Inhaled LPS challenge significantly increased sputum percent neutrophils (%PMNs) (p=0.003) and neutrophils per mg (PMNs/mg) of sputum (p=0.01) at 6 hours compared to post-treatment sputum during the placebo period

    PMID 28736267 · one of two readings recorded this

  • total sputum mucins after LPS challenge

    decreases, p = 0.03

    we detected significantly less total sputum mucins during the active treatment period compared to placebo (=0.03)

    PMID 28736267 · one of two readings recorded this

  • change in LPS-induced sputum neutrophilia (post-challenge % sputum PMNs minus post-treatment % sputum PMNs) after inhaled endotoxin challenge (20,000 EU), gamma-tocopherol-enriched supplement 1200 mg daily for 7 days (healthy volunteers) or 14 days (mild asthmatics) versus safflower oil placebo, pooled post hoc across two crossover trials

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV.

    PMID 30660638 · one of two readings recorded this

  • effect of γT on LPS-induced sputum PMN recruitment, effect modification by categorical BMI (model with BMI, GSTM1 and asthma)

    no effect, p = 0.44

    including categorical BMI, GSTM1 genotype, and presence of asthma as independent variables yielded similar results [p=0.44 (−17.43, 7.46), 0.51 (−15.49, 7.57), 0.69 (−14.40, 9.49), respectively]

    PMID 30660638 · one of two readings recorded this

  • effect of γT on LPS-induced sputum PMN recruitment, effect modification by categorical BMI

    no effect, p = 0.6

    no effect modification by categorical BMI (<25 or ≥25) [p=0.60 (−14.24, 8.13); Figure 2a]

    PMID 30660638 · one of two readings recorded this

  • effect of γT on LPS-induced sputum PMN recruitment, effect modification by GSTM1 genotype (model with BMI, GSTM1 and asthma)

    no effect, p = 0.51

    including categorical BMI, GSTM1 genotype, and presence of asthma as independent variables yielded similar results [p=0.44 (−17.43, 7.46), 0.51 (−15.49, 7.57), 0.69 (−14.40, 9.49), respectively]

    PMID 30660638 · one of two readings recorded this

  • effect of γT on LPS-induced sputum PMN recruitment, effect modification by GSTM1 genotype

    no effect, p = 0.4

    or GSTM1 genotype [p=0.40 (−16.02, 6.20); Figure 2b]

    PMID 30660638 · one of two readings recorded this

  • effect of γT on LPS-induced sputum PMN recruitment, effect modification by presence of asthma (model with BMI, GSTM1 and asthma)

    no effect, p = 0.69

    including categorical BMI, GSTM1 genotype, and presence of asthma as independent variables yielded similar results [p=0.44 (−17.43, 7.46), 0.51 (−15.49, 7.57), 0.69 (−14.40, 9.49), respectively]

    PMID 30660638 · one of two readings recorded this

  • LPS-induced sputum neutrophilia, calculated as post-challenge % sputum PMNs minus post-treatment % sputum PMNs, 6 h after inhaled LPS (20,000 endotoxin units), in healthy volunteers and mild asthmatics combined, and whether BMI or GSTM1 genotype modified the γT effect (post hoc pooled analysis of two crossover trials)

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV.

    PMID 30660638 · one of two readings recorded this

  • LPS-induced sputum PMN recruitment, effect modification by categorical BMI

    no effect, p = 0.67

    there was no effect modification by categorical BMI [p=0.67 (−14.25, 9.12)]

    PMID 30660638 · one of two readings recorded this

  • LPS-induced sputum PMN recruitment, effect modification by GSTM1 genotype

    no effect, p = 0.33

    GSTM1 genotype [p=0.33 (−18.25, 5.95)] on sputum PMN recruitment following inhaled LPS challenge

    PMID 30660638 · one of two readings recorded this

  • LPS-induced sputum PMN recruitment

    decreases

    Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV

    PMID 30660638 · one of two readings recorded this

  • LPS-induced sputum PMN recruitment

    decreases

    Active treatment with γT attenuated sputum PMN recruitment following inhaled LPS challenge in both HV and AV

    PMID 30660638 · one of two readings recorded this

  • central region Ave30Clr clearance

    unclear, p = 0.07

    central Ave30Clr: 12.6% [± 9.2% SD] baseline vs 9.8% [± 8.5%] post-O3, p=0.07

    PMID 32727225 · one of two readings recorded this

  • central region Ave30Clr clearance

    no effect, p = 0.86

    12.6% [± 9.2%] baseline vs 12.1% [± 6.8%] post-O3, p=0.86

    PMID 32727225 · one of two readings recorded this

  • change in induced-sputum percentage neutrophils (PMN) from before to 6 hours after a 3-hour 0.25 ppm ozone challenge, after a 4-dose gamma-tocopherol-enriched supplement (89.5% d-gamma tocopherol, total tocopherols 93.2%, about 600 mg per geltab, two geltabs every 12 h) versus safflower-oil placebo

    mean increase in sputum %PMN 36.5 percentage points following placebo versus 34.1 following gamma tocopherol

    Not recorded as a finding: this platform holds no node for the endpoint

    However, γT supplementation did not attenuate O3-induced neutrophilic airway inflammation compared to placebo (mean increase in sputum %PMN of 36.5 percentage points [± 20.2] following placebo versus 34.1 percentage points [± 20.2] following γT, p>0.9).

    PMID 32727225 · one of two readings recorded this

  • induced sputum neutrophil percentage (%PMN) increase from pre-ozone to 6 h after 0.25 ppm ozone for 3 h; pre-ozone induced sputum eosinophil percentage; sputum cytokines IL-1β, IL-6, IL-8 and TNFα by V-PLEX immunoassay; mucociliary clearance of inhaled 99mTc sulfur colloid by gamma scintigraphy (whole lung and central region); in 7 volunteers for the sputum endpoints

    no effect, mean ozone-induced rise in sputum %PMN 36.5 percentage points after placebo versus 34.1 after γT; no attenuation

    Not recorded as a finding: this platform holds no node for the endpoint

    However, γT supplementation did not attenuate O3-induced neutrophilic airway inflammation compared to placebo (mean increase in sputum %PMN of 36.5 percentage points [± 20.2] following placebo versus 34.1 percentage points [± 20.2] following γT, p>0.9).

    PMID 32727225 · one of two readings recorded this

  • O3-induced increase in sputum %PMN

    no effect, p = 0.9

    mean increase in sputum %PMN of 36.5 percentage points [± 20.2] following placebo versus 34.1 percentage points [± 20.2] following γT, p>0.9

    PMID 32727225 · one of two readings recorded this

  • pre-O3 sputum eosinophils

    no effect, p = 0.56

    mean of 2.2% sputum eosinophils [± 3.7 SD] following placebo treatment and 3.4% sputum eosinophils [± 4.3] following γT treatment, p=0.56

    PMID 32727225 · one of two readings recorded this

  • sputum cytokines after O3

    no effect

    no difference in sputum cytokines following γT supplementation compared to placebo (data not shown)

    PMID 32727225 · one of two readings recorded this

  • sputum inflammatory cytokines (IL-1β, IL-6, IL-8, TNFα) change from baseline after O3

    no effect

    We found no significant change in sputum inflammatory cytokines (Interleukin (IL)-1 β, IL-6, IL-8 and TNFα) from baseline following O3 exposure

    PMID 32727225 · one of two readings recorded this

  • sputum percentage of eosinophils after O3

    no effect

    with no significant effect on sputum percentage of eosinophils

    PMID 32727225 · one of two readings recorded this

  • sputum percentage of neutrophils after O3

    increases

    O3 exposure significantly increased sputum percentage of neutrophils during both the placebo and γT treatment periods

    PMID 32727225 · one of two readings recorded this

  • whole lung average 120 minute clearance (Ave120Clr)

    no effect

    mean average 120 minute clearance (Ave120Clr) of 21% (± 7% SD) at baseline, 21% (± 7%) post-O3 during placebo, and 23% (± 7%) post-O3 during γT treatment

    PMID 32727225 · one of two readings recorded this

  • 24-h cumulative urinary sodium excretion (mEq), luteal phase

    mean difference 10.6 mEq (95% CI -0.1, 21.4, power 55%), p = 0.052

    Not recorded as a finding: no outcome node for urinary sodium excretion (serum-sodium is a different matrix); result also not significant with no absence stated in words

    In the luteal phase, the mean difference in 24-h urinary sodium excretion between γ-Toc and placebo intake was 10.6 mEq (95% CI: -0.1, 21.4, p = 0.052, power 55%).

    PMID 37118716 · one of two readings recorded this

  • 24-h urinary sodium excretion

    unclear, p = 0.052

    In the luteal phase, the mean difference in 24-h urinary sodium excretion between γ-Toc and placebo intake was 10.6 mEq (95% CI: -0.1, 21.4, p = 0.052, power 55%)

    PMID 37118716 · one of two readings recorded this

  • cumulative 24-h urinary sodium excretion (mEq), luteal phase, 25 participants

    mean difference 10.6 mEq (95% CI -0.1, 21.4), power 55%, p = 0.052

    Not recorded as a finding: No outcome node for urinary sodium excretion (CAT:outcome/serum-sodium is serum). The estimate straddles zero and the sentence states no direction word.

    In the luteal phase, the mean difference in 24-h urinary sodium excretion between γ-Toc and placebo intake was 10.6 mEq (95% CI: -0.1, 21.4, p = 0.052, power 55%).

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary potassium excretion

    no effect

    There was no significant between-supplement difference in cumulative urinary potassium excretion (data not shown)

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    increases, p = 0.026

    p-value vs. placebo intake | 0.026 | 0.630

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    no effect, p = 0.63

    p-value vs. placebo intake | 0.026 | 0.630

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    no effect, p = 0.464

    p-value vs. placebo intake | 0.052 | 0.464

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    γ-Toc intake | 145.7 ± 9.4 | 346.0 ± 16.7

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    γ-Toc intake | 145.7 ± 9.4 | 346.0 ± 16.7

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    γ-Toc intake | 151.1 ± 7.7 | 353.1 ± 13.6

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    γ-Toc intake | 151.1 ± 7.7 | 353.1 ± 13.6

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Urinary sodium excretion (mEq) | Follicular phase | 155.2 ± 9.7 | 383.2 ± 13.7

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Urinary sodium excretion (mEq) | Follicular phase | 155.2 ± 9.7 | 383.2 ± 13.7

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Urinary sodium excretion (mEq) | Follicular phase | 143.9 ± 8.0 | 359.3 ± 13.6

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Urinary sodium excretion (mEq) | Follicular phase | 143.9 ± 8.0 | 359.3 ± 13.6

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Placebo intake | 129.5 ± 8.6 | 334.7 ± 17.3

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Placebo intake | 129.5 ± 8.6 | 334.7 ± 17.3

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Placebo intake | 139.4 ± 7.1 | 343.8 ± 13.4

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    Placebo intake | 139.4 ± 7.1 | 343.8 ± 13.4

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    unclear, p = 0.001

    p-value vs. luteal phase | 0.001 | < 0.001

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    unclear, p = 0.001

    p-value vs. luteal phase | 0.001 | < 0.001

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    no effect, p = 0.587

    p-value vs. luteal phase | 0.587 | 0.250

    PMID 37118716 · one of two readings recorded this

  • cumulative urinary sodium excretion

    no effect, p = 0.25

    p-value vs. luteal phase | 0.587 | 0.250

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume (mL) over 24 h and 48 h

    no effect

    Not recorded as a finding: Node CAT:outcome/urine-output fits, but the only sentence says 'between-supplement' and never names γ-Toc, so it does not support the claim on its own and the arm is only resolved from Methods.

    There was no significant between-supplement difference in urine volume (Table 2 a).

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    no effect, p = 0.591

    p-value vs. placebo intake | 0.591 | 0.436

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    no effect, p = 0.436

    p-value vs. placebo intake | 0.591 | 0.436

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    no effect, p = 0.734

    p-value vs. placebo intake | 0.734 | 0.981

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    no effect, p = 0.981

    p-value vs. placebo intake | 0.734 | 0.981

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    γ-Toc intake | 1433 ± 90 | 3225 ± 158

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    γ-Toc intake | 1433 ± 90 | 3225 ± 158

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    γ-Toc intake | 1480 ± 65 | 3305 ± 119

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    γ-Toc intake | 1480 ± 65 | 3305 ± 119

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Urine volume (mL) | Follicular phase | 1563 ± 88 | 3526 ± 136

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Urine volume (mL) | Follicular phase | 1563 ± 88 | 3526 ± 136

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Urine volume (mL) | Follicular phase | 1478 ± 70 | 3399 ± 112

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Urine volume (mL) | Follicular phase | 1478 ± 70 | 3399 ± 112

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Placebo intake | 1369 ± 87 | 3235 ± 162

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Placebo intake | 1369 ± 87 | 3235 ± 162

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Placebo intake | 1450 ± 67 | 3283 ± 116

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    Placebo intake | 1450 ± 67 | 3283 ± 116

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    unclear, p = 0.039

    p-value vs. luteal phase | 0.039 | 0.031

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    unclear, p = 0.031

    p-value vs. luteal phase | 0.039 | 0.031

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    no effect, p = 0.746

    p-value vs. luteal phase | 0.746 | 0.309

    PMID 37118716 · one of two readings recorded this

  • cumulative urine volume

    no effect, p = 0.309

    p-value vs. luteal phase | 0.746 | 0.309

    PMID 37118716 · one of two readings recorded this

  • days from E-D1 to next menstrual onset

    no effect

    During γ-Toc and placebo intake, E-D1 in the luteal phase was 6.0 ± 0.5 days and 7.2 ± 0.5 days, respectively, before the onset of the next menstrual period

    PMID 37118716 · one of two readings recorded this

  • MDQ arousal

    no effect, p = 0.195

    Arousal | 2.1 ± 0.7 | 1.3 ± 0.5 | 0.195

    PMID 37118716 · one of two readings recorded this

  • MDQ autonomic reactions

    increases, p = 0.004

    Autonomic reactions | 0.2 ± 0.2 | 1.1 ± 0.4 | 0.004

    PMID 37118716 · one of two readings recorded this

  • MDQ behavior change

    increases, p = 0.001

    Behavior change | 2.0 ± 0.6 | 5.6 ± 1.0 | < 0.001

    PMID 37118716 · one of two readings recorded this

  • MDQ concentration

    no effect, p = 0.079

    During the luteal phase, γ-Toc intake resulted in non-significantly lower MDQ scores for “concentration” than placebo intake (p = 0.079)

    PMID 37118716 · one of two readings recorded this

  • MDQ concentration

    increases, p = 0.006

    The luteal phase showed significantly higher MDQ scores for “concentration” and “negative affect” than the follicular phase (p = 0.006 and p = 0.049, respectively

    PMID 37118716 · one of two readings recorded this

  • MDQ control

    increases, p = 0.005

    Control | 0.3 ± 0.2 | 1.8 ± 0.6 | 0.005

    PMID 37118716 · one of two readings recorded this

  • MDQ impaired concentration

    increases, p = 0.003

    Impaired concentration | 2.1 ± 0.8 | 5.6 ± 1.1 | 0.003

    PMID 37118716 · one of two readings recorded this

  • MDQ negative affect

    increases, p = 0.001

    Negative affect | 0.8 ± 0.4 | 5.4 ± 1.0 | < 0.001

    PMID 37118716 · one of two readings recorded this

  • MDQ negative affect

    increases, p = 0.049

    The luteal phase showed significantly higher MDQ scores for “concentration” and “negative affect” than the follicular phase (p = 0.006 and p = 0.049, respectively

    PMID 37118716 · one of two readings recorded this

  • MDQ pain

    increases, p = 0.001

    Pain | 1.9 ± 0.5 | 6.9 ± 1.1 | < 0.001

    PMID 37118716 · one of two readings recorded this

  • MDQ water retention

    increases, p = 0.001

    Water retention | 2.1 ± 0.4 | 9.6 ± 0.8 | < 0.001

    PMID 37118716 · one of two readings recorded this

  • morning serum progesterone and estradiol

    no effect

    There were no significant between-supplement differences in the morning serum progesterone and estradiol levels on E-D1 in the luteal phase

    PMID 37118716 · one of two readings recorded this

  • plasma aldosterone

    no effect, p = 0.199

    E-D1 | 189.3 ± 16.8 | 317.6 ± 29.1 | < 0.001 | 278.3 ± 34.9 | 0.199

    PMID 37118716 · one of two readings recorded this

  • plasma aldosterone

    increases, p = 0.001

    E-D1 | 189.3 ± 16.8 | 317.6 ± 29.1 | < 0.001 | 278.3 ± 34.9 | 0.199

    PMID 37118716 · one of two readings recorded this

  • plasma ANP

    no effect, p = 0.059

    E-D1 | 27.0 ± 2.8 | 21.9 ± 1.6 | 0.041 | 25.7 ± 2.3 | 0.059

    PMID 37118716 · one of two readings recorded this

  • plasma ANP

    decreases, p = 0.041

    E-D1 | 27.0 ± 2.8 | 21.9 ± 1.6 | 0.041 | 25.7 ± 2.3 | 0.059

    PMID 37118716 · one of two readings recorded this

  • plasma atrial natriuretic peptide (ANP), pg/mL, E-D3 morning

    increases, significantly increased with γ-Toc versus placebo in E-D3 mornings; no estimate in the sentence

    Not recorded as a finding: No outcome node for plasma ANP.

    In the luteal phase, γ-Toc intake significantly increased plasma ANP levels in E-D3 mornings, compared with placebo intake.

    PMID 37118716 · one of two readings recorded this

  • plasma atrial natriuretic peptide (ANP), pg/mL

    increases

    Not recorded as a finding: no outcome node for plasma ANP; assay not stated

    In the luteal phase, γ-Toc intake significantly increased plasma ANP levels in E-D3 mornings, compared with placebo intake.

    PMID 37118716 · one of two readings recorded this

  • plasma γ-CEHC

    increases, p = 0.001

    γ-Toc intake significantly increased plasma γ-CEHC levels in the mornings of E-D1 (0.08 ± 0.02 μM vs. 2.87 ± 0.29 μM, p < 0.001)

    PMID 37118716 · one of two readings recorded this

  • plasma γ-tocopherol

    increases, p = 0.001

    γ-Toc intake significantly increased plasma γ-Toc levels in the mornings of E-D1 (2.5 ± 0.2 μM vs. 16.3 ± 1.1 μM, p < 0.001)

    PMID 37118716 · one of two readings recorded this

  • rate of change in plasma volume

    no effect

    Moreover, there was no significant between-supplement difference in the rate of change in plasma volume from E-D1 morning to E-D3 morning

    PMID 37118716 · one of two readings recorded this

  • serum sodium, potassium, osmolality, protein, hemoglobin and hematocrit

    no effect

    There were no significant between-supplement differences in serum sodium, serum potassium, osmolality, protein concentration, hemoglobin, and hematocrit levels in the mornings of E-D1 and E-D3

    PMID 37118716 · one of two readings recorded this

  • serum sodium, serum potassium, osmolality, protein, haemoglobin and haematocrit, mornings of E-D1 and E-D3

    no effect, no significant between-supplement differences; no estimates in the sentence

    Not recorded as a finding: Nodes CAT:outcome/serum-sodium, serum-potassium, blood-haemoglobin and haematocrit exist, but the sentence covers six analytes in one statement with no estimates and says 'between-supplement' without naming γ-Toc, so it does not support a claim on its own.

    There were no significant between-supplement differences in serum sodium, serum potassium, osmolality, protein concentration, hemoglobin, and hematocrit levels in the mornings of E-D1 and E-D3.

    PMID 37118716 · one of two readings recorded this

  • thigh circumference in the standing position, tape, mornings of E-D2 and E-D3

    decreases, significantly lower with γ-Toc than placebo; no estimate in the sentence

    Not recorded as a finding: No outcome node for limb circumference (CAT:outcome/waist-circumference is waist girth only).

    In the mornings of E-D2 and E-D3, thigh circumference was significantly lower with γ-Toc intake than with placebo intake (Fig. [i] and c [ii]).

    PMID 37118716 · one of two readings recorded this

  • thigh circumference, tape measure in standing position

    decreases

    Not recorded as a finding: no outcome node for limb circumference

    In addition, γ-Toc intake resulted in a significantly lower thigh circumference than the placebo intake.

    PMID 37118716 · one of two readings recorded this

  • thigh circumference

    decreases

    In the mornings of E-D2 and E-D3, thigh circumference was significantly lower with γ-Toc intake than with placebo intake

    PMID 37118716 · one of two readings recorded this

  • VAS abdominal bloating

    increases

    During placebo intake, the VAS scores for “breast tenderness/soreness” (Supplementary Fig. 1 c), “abdominal bloating” (Supplementary Fig. 1 d), and “irritability/anger” (Supplementary Fig. 1 i) were significantly higher in the luteal phase than in the follicular phase

    PMID 37118716 · one of two readings recorded this

  • VAS breast tenderness/soreness

    increases

    During placebo intake, the VAS scores for “breast tenderness/soreness” (Supplementary Fig. 1 c), “abdominal bloating” (Supplementary Fig. 1 d), and “irritability/anger” (Supplementary Fig. 1 i) were significantly higher in the luteal phase than in the follicular phase

    PMID 37118716 · one of two readings recorded this

  • VAS fatigue

    decreases

    the VAS scores for “fatigue” (Supplementary Fig. 2 g) and “irritability/angry” (Supplementary Fig. 2 i) were significantly lower with γ-Toc intake than with placebo intake

    PMID 37118716 · one of two readings recorded this

  • VAS fatigue

    unclear, p = 0.075

    The mean differences in scores for “heavy legs,” “fatigue,” and “irritability/anger” on E-D2 were -7.9 mm (95% confidence interval (CI): -16.2, 0.4, p = 0.062, power 46%), -8.7 mm (95% CI: -18.4, 0.9, p = 0.075, power 43%), and -5.5 mm (95% CI: -12.0, 1.1, p = 0.097, power 38%)

    PMID 37118716 · one of two readings recorded this

  • VAS heavy legs

    unclear, p = 0.05

    there were almost significant between-supplement differences in the VAS scores for “heavy legs” (p = 0.050

    PMID 37118716 · one of two readings recorded this

  • VAS heavy legs

    unclear, p = 0.062

    The mean differences in scores for “heavy legs,” “fatigue,” and “irritability/anger” on E-D2 were -7.9 mm (95% confidence interval (CI): -16.2, 0.4, p = 0.062, power 46%), -8.7 mm (95% CI: -18.4, 0.9, p = 0.075, power 43%), and -5.5 mm (95% CI: -12.0, 1.1, p = 0.097, power 38%)

    PMID 37118716 · one of two readings recorded this

  • VAS irritability/anger

    decreases

    the VAS scores for “fatigue” (Supplementary Fig. 2 g) and “irritability/angry” (Supplementary Fig. 2 i) were significantly lower with γ-Toc intake than with placebo intake

    PMID 37118716 · one of two readings recorded this

  • VAS irritability/anger

    increases

    During placebo intake, the VAS scores for “breast tenderness/soreness” (Supplementary Fig. 1 c), “abdominal bloating” (Supplementary Fig. 1 d), and “irritability/anger” (Supplementary Fig. 1 i) were significantly higher in the luteal phase than in the follicular phase

    PMID 37118716 · one of two readings recorded this

  • VAS scores (100-mm) for the single items 'fatigue' and 'irritability/anger' within a 10-item premenstrual symptom VAS, whole evaluation period

    decreases, significantly lower with γ-Toc than placebo; no estimate in the sentence

    Not recorded as a finding: Node CAT:outcome/subjective-fatigue needs a named validated self-report instrument measuring fatigue specifically; the paper uses one item of a 10-item premenstrual-symptom VAS, so this is endpoint_near_miss. Irritability/anger has no node.

    Moreover, the VAS scores for “fatigue” (Supplementary Fig. 2 g) and “irritability/angry” (Supplementary Fig. 2 i) were significantly lower with γ-Toc intake than with placebo intake.

    PMID 37118716 · one of two readings recorded this

  • VAS scores, all 10 premenstrual symptom items

    increases

    The VAS scores for all 10 items were significantly higher in the luteal phase than in the follicular phase

    PMID 37118716 · one of two readings recorded this